Macrophage specific drug delivery in experimental leishmaniasis.
Macrophage-specific delivery systems are the subject of much interest nowadays, because of the fact that macrophages act as host cells for many parasites and bacteria, which give rise to outbreak of so many deadly diseases(eg. leishmaniasis, tuberculosis etc.) in humans. To combat these deadly diseases initially macrophage specific liposomal delivery system were thought of and tested in vivo against experimental leishmaniasis in hamsters using a series of indigenous or synthetic antileishmanial compounds and the results were critically discussed. In vitro testing was also done against macrophages infected with Leishmania donovani, the causative agent for visceral leishmaniasis. The common problem of liposome therapy being their larger size, stability and storage, non-ionic surfactant vesicles, niosomes were prepared, for their different drug distribution and release characteristics compared to liposomes. When tested in vivo, the retention capacity of niosomes was found to be higher than that of liposomes due to the absence of lipid molecules and their smaller size. Thus the therapeutic efficacy of certain antileishmanial compounds was found to be better than that in the liposomal form. The niosomes, being cheaper, less toxic, biodegradable and non-immunogenic, were considered for sometime as suitable alternatives to liposomes as drug carriers. Besides the advent of other classical drugs carriers(e.g. neoglycoproteins), the biggest challenge came from polymeric delivery vehicles, specially the polymeric nanoparticles which were made of cost effective biodegradable polymers and different natural polymers. Because of very small size and highly stable nature, use of nanoparticles as effective drug carriers has been explored in experimental leishmaniasis using a series of antileishmanial compounds, both of indigenous and synthetic origin. The feasibility of application in vivo, when tested for biological as well as for other physicochemical parameters, the polymeric nanoparticles have turned out to be the best and thus may be projected for effective use in the clinics.
Basu
Mukul Kumar
MK
Indian Institute of Chemical Biology, 4, Raja SC Mullick Road, Kolkata-700032, India. biomembrane@iicb.res.in
Lala
Sanchaita
S
D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use*; D006224:Cricetinae; D003412:Cricetulus; D004337:Drug Carriers; D016503:Drug Delivery Systems; D005544:Forecasting; D006027:Glycosides / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D007893:Leishmania donovani; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D008081:Liposomes; D008264:Macrophages / Q000187:drug effects*; D008863:Microspheres; D036103:Nanotechnology; D011108:Polymers; D013329:Structure-Activity Relationship
D000981:Antiprotozoal Agents; D004337:Drug Carriers; D006027:Glycosides; D008081:Liposomes; D011108:Polymers